: Projected for 26% revenue growth in 2026, largely supported by surging demand for weight-loss drugs Mounjaro and Zepbound.

: Remains a top growth pick with a $250 price target from CFRA. Revenue grew 73% year-over-year, driven by the ongoing AI infrastructure boom.

: A top choice for undervalued global software exposure. Defensive & Income Picks

: Recommended for both growth and safety, offering a dividend yield of approximately 2.3%.

: Favored for its application-specific integrated circuit (ASIC) business; CFRA projects semiconductor revenue to triple by 2027.

: Estimated 39% upside with accelerating revenue in both commercial and government sectors.

: High analyst consensus score for its role in networking infrastructure. Healthcare & Biotech

: Shows a 44% implied upside as it expands return on tangible common equity following the lifting of its asset cap.